CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 546 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ribociclib succinate
CAS:Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).Formula:C27H36N8O5Purity:99.9%Color and Shape:SolidMolecular weight:552.63Ref: TM-T15732
2mg34.00€5mg49.00€10mg70.00€25mg92.00€50mg109.00€100mg165.00€200mg258.00€500mg459.00€1mL*10mM (DMSO)60.00€Ca2+ channel agonist 1
CAS:Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.Formula:C19H26N6OPurity:97.71%Color and Shape:SolidMolecular weight:354.45Ref: TM-T10659
1mg92.00€5mg178.00€10mg269.00€25mg429.00€50mg610.00€100mg820.00€200mg1,071.00€1mL*10mM (DMSO)207.00€Trilaciclib hydrochloride
CAS:Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Formula:C24H32Cl2N8OPurity:99.69% - 99.89%Color and Shape:SolidMolecular weight:519.47CDK4/6-IN-2
CAS:CDK4/6-IN-2 是一种CDK4和CDK6抑制剂，IC50分别为 2.7 和 16 nM。Formula:C27H32F2N8Purity:99.47%Color and Shape:SolidMolecular weight:506.59NU6140
CAS:NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).Formula:C23H30N6O2Purity:98.33%Color and Shape:SolidMolecular weight:422.52Ref: TM-T16359
2mg39.00€5mg60.00€10mg92.00€25mg177.00€50mg285.00€100mg414.00€200mg580.00€1mL*10mM (DMSO)67.00€Lerociclib dihydrochloride
CAS:Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/Formula:C26H36Cl2N8OPurity:97.4%Color and Shape:SolidMolecular weight:547.52Amantadine hydrochloride
CAS:Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.Formula:C10H18ClNPurity:99.98%Color and Shape:Solid CrystallineMolecular weight:187.71Nimbolide
CAS:Nimbolide, from neem, inhibits CDK4/6, NF-κB, Wnt, PI3K-Akt, MAPK, JAK-STAT pathways and induces apoptosis.Formula:C27H30O7Purity:95.84% - 99.4%Color and Shape:SolidMolecular weight:466.52Ref: TM-T16324
1mg67.00€5mg167.00€10mg289.00€25mg595.00€50mg820.00€100mg1,108.00€200mg1,440.00€1mL*10mM (DMSO)180.00€CDKI-73
CAS:CDKI-73: strong CDK9 blocker, Ki 4 nM, kills CLL cells selectively, aids cisplatin.Formula:C15H15FN6O2S2Purity:98.11%Color and Shape:SolidMolecular weight:394.45Ref: TM-T14919
1mg136.00€2mg178.00€5mg278.00€10mg399.00€25mg658.00€50mg888.00€100mg1,251.00€1mL*10mM (DMSO)290.00€CDK2-IN-4
CAS:CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.Formula:C23H18N6O2SPurity:97.24% - 99.10%Color and Shape:SolidMolecular weight:442.49Ref: TM-T14916
1mg82.00€5mg192.00€10mg304.00€25mg522.00€50mg713.00€100mg1,018.00€1mL*10mM (DMSO)212.00€hSMG-1 inhibitor 11j
CAS:hSMG-1 inhibitor 11j: pyrimidine, IC50=0.11 nM, >455x selective vs. mTOR/PI3Kα/γ/CDK1/CDK2; cancer research use.
Formula:C27H28ClN7O3SPurity:99.22% - 99.65%Color and Shape:SolidMolecular weight:566.07MBQ-167
CAS:MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).Formula:C22H18N4Purity:98.07% - 99.52%Color and Shape:SolidMolecular weight:338.41Ref: TM-T16021
1mg34.00€2mg49.00€5mg74.00€10mg105.00€25mg197.00€50mg356.00€100mg537.00€1mL*10mM (DMSO)82.00€GSK-3 inhibitor 4
CAS:Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.Formula:C22H15F2N5OPurity:99.82%Color and Shape:SoildMolecular weight:403.38Ref: TM-T77341
1mg315.00€5mg873.00€10mg1,080.00€25mg1,431.00€50mg1,783.00€100mg2,250.00€500mg3,537.00€AZ1495
CAS:AZ1495: oral IRAK4 inhibitor (IC50: 5 nM), IRAK1 (23 nM), treats MYD88L265P DLBCL.Formula:C21H31N5O2Purity:98.81%Color and Shape:SolidMolecular weight:385.5Ref: TM-T14367
1mg93.00€5mg156.00€10mg245.00€25mg349.00€50mg494.00€100mg750.00€200mg1,009.00€1mL*10mM (DMSO)170.00€(R)-CR8
CAS:(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.
Formula:C24H29N7OPurity:98.41%Color and Shape:SolidMolecular weight:431.53Simurosertib
CAS:Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).Formula:C17H19N5OSPurity:99.93% - 99.93%Color and Shape:SolidMolecular weight:341.43Ref: TM-T12642L
1mg62.00€5mg150.00€10mg203.00€25mg379.00€50mg533.00€100mg737.00€1mL*10mM (DMSO)157.00€XPW1
CAS:XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.Formula:C36H39ClFN7O2Purity:98.08%Color and Shape:SoildMolecular weight:656.19BRD6989
CAS:BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.Formula:C16H16N4Purity:99.43%Color and Shape:SolidMolecular weight:264.33Ref: TM-T14778
1mg34.00€5mg66.00€10mg92.00€25mg177.00€50mg268.00€100mg398.00€200mg575.00€1mL*10mM (DMSO)73.00€Cirtuvivint
CAS:Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.Formula:C24H25N7OPurity:99.95% - 99.96%Color and Shape:SolidMolecular weight:427.5Samuraciclib hydrochloride
CAS:Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).Formula:C22H31ClN6OPurity:98.99% - 99.8%Color and Shape:SolidMolecular weight:430.97Ref: TM-T10898
1mg108.00€2mg147.00€5mg222.00€10mg335.00€25mg595.00€50mg847.00€100mg1,153.00€1mL*10mM (DMSO)245.00€NVP-2
CAS:NVP-2 selectively inhibits CDK9 (IC50: 0.514 nM), prompts apoptosis, and affects other CDKs (IC50: 0.584-0.706 μM).Formula:C27H37ClN6O2Purity:99.13%Color and Shape:SolidMolecular weight:513.07Ref: TM-T16363
1mg52.00€2mg74.00€5mg113.00€10mg192.00€25mg416.00€50mg615.00€100mg875.00€1mL*10mM (DMSO)128.00€Garcinone C
CAS:Garcinone C, a xanthone from Garcinia oblongifolia, is anti-inflammatory, promotes healing, and may fight some cancers.Formula:C23H26O7Purity:99.13% - 99.92%Color and Shape:SolidMolecular weight:414.45Cyclin K degrader 1
Cyclin K degrader 1 is a Cyclin K degrader.Cyclin K degrader 1 is a degrader converted from AT-7519.Cyclin K degrader 1 has weak degrading activity against Cyclin K but does not result in a sustained decrease in degradation affinity.Cyclin K degrader 1 is a degrader converted from AT-7519.Formula:C23H17Cl2N5O2Purity:99.76%Color and Shape:SolidMolecular weight:466.32(±)-Enitociclib
CAS:(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.Formula:C19H18F2N4O2SPurity:99.29%Color and Shape:SolidMolecular weight:404.43Ref: TM-T13467
1mg34.00€5mg84.00€10mg114.00€25mg205.00€50mg334.00€100mg537.00€200mg762.00€1mL*10mM (DMSO)93.00€JWZ-5-13
JWZ-5-13 is an effective CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 also exhibits antitumor activity.Formula:C54H66N10O6SMolecular weight:982.48875MeBIO
CAS:MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Formula:C17H12BrN3O2Purity:99.64%Color and Shape:SolidMolecular weight:370.2Ref: TM-T21966
1mg39.00€5mg74.00€10mg117.00€25mg220.00€50mg354.00€100mg520.00€500mg1,130.00€1mL*10mM (DMSO)86.00€CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Formula:C38H42N12O10S2Color and Shape:SolidMolecular weight:890.94BSJ-5-63
CAS:BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.Formula:C52H74ClN9O6S2Color and Shape:SolidMolecular weight:1020.78(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).Formula:C24H25Cl2F3N4OPurity:98%Color and Shape:SolidMolecular weight:513.38FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Color and Shape:LiquidPROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.
Formula:C40H42N12O5Molecular weight:770.34011Olomoucine
CAS:Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.
Formula:C15H18N6OPurity:99.77%Color and Shape:White Crystalline PowderMolecular weight:298.34dCeMM3
CAS:dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.
Formula:C14H11ClN4OSPurity:98.48% - 99.41%Color and Shape:SolidMolecular weight:318.78LSN3106729 hydrochloride
CAS:LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.Formula:C25H29ClF2N8OColor and Shape:SoildMolecular weight:531.00Maleimide-PEG8-Val-Ala-PAB-SNS032
Maleimide-Val-Ala-PAB-SNS032 is a conjugated compound used as an ADC toxin and linker. SNS032 acts as a CDK inhibitor, reducing cancer cell viability and arresting the cell cycle at the G1/S phase. Maleimide-Val-Ala-PAB functions as a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 is utilized in the synthesis of ADC molecules.Formula:C59H87N9O18S2Molecular weight:1273.56105CDK9 degrader-1
CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.Formula:C32H34Cl2N6O4Color and Shape:SolidMolecular weight:637.56GW297361
CAS:GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1Formula:C16H12N4O3S2Purity:98.30%Color and Shape:SolidMolecular weight:372.42Anticancer agent 264
Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.Formula:C23H18ClF5N6OColor and Shape:SolidMolecular weight:524.87IMPDH2-IN-4
IMPDH2-IN-4 (compound 2d) is a Mycophenolic acid analog and a selective IMPDH2 inhibitor with a Ki of 1.8 μM. It exhibits potent cytotoxic activity against osteosarcoma cancer cell lines. Additionally, IMPDH2-IN-4 demonstrates high affinity for VEGFR-2, CDK2, and IMPDH.Formula:C35H34O6SiColor and Shape:SolidMolecular weight:578.73AM5992
CAS:AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.Formula:C27H33FN8OPurity:98%Color and Shape:SoildMolecular weight:504.6CDK2-IN-7
CAS:CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).Formula:C24H30N6O4SColor and Shape:SolidMolecular weight:498.6[pThr3]-CDK5 Substrate
CAS:[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].Formula:C53H100N15O15PPurity:98%Color and Shape:SolidMolecular weight:1218.43PROTAC CDK9 degrader-5
CAS:PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.Formula:C42H48Cl2N8O9Purity:98%Color and Shape:SolidMolecular weight:879.78JHD205
JHD205 is an inhibitor of CDK4/6.Formula:C32H40F2N8OColor and Shape:SolidMolecular weight:590.71NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Formula:C40H29ClIrN5OColor and Shape:SolidMolecular weight:823.36Roccellic Acid
CAS:Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.Formula:C17H32O4Color and Shape:SolidMolecular weight:300.43JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.1613-Methylthienyl-carbonyl-JNJ-7706621
CAS:Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Formula:C14H14N6O3S2Color and Shape:SolidMolecular weight:378.43CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Color and Shape:Odour SolidBLINK15
BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.Color and Shape:Odour SolidCDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Formula:C26H42ClN7O4Color and Shape:SolidMolecular weight:552.12WAY-322243
CAS:WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Formula:C18H18N2O2SPurity:99.88%Color and Shape:SoildMolecular weight:326.41Abemaciclib metabolite M18
CAS:Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Formula:C25H28F2N8OPurity:98%Color and Shape:SolidMolecular weight:494.54CDK2/4-IN-1
CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.Color and Shape:Odour Solid(E/Z)-THZ1 2HCl
CAS:THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.
Formula:C31H30Cl3N7O2Purity:99.51%Color and Shape:SolidMolecular weight:638.98PROTAC CDK9 degrader-7
CAS:PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (Formula:C43H50Cl2N8O9Color and Shape:SoildMolecular weight:893.81BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Formula:C43H48N10O8Color and Shape:SolidMolecular weight:832.9CDK9/EZH2-IN-1
CAS:CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.Formula:C47H59N11O4S2Color and Shape:SolidMolecular weight:906.17CDK7-IN-6
CAS:CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.Formula:C26H34ClN9OColor and Shape:SolidMolecular weight:524.07JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Formula:C22H22ClN7OColor and Shape:SolidMolecular weight:435.92PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Formula:C43H51FN12O7Color and Shape:SolidMolecular weight:866.94Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquirePROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Formula:C43H56N10O5Color and Shape:SolidMolecular weight:792.97CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Formula:C24H32F3N5O2Color and Shape:SolidMolecular weight:479.548A-130A
CAS:A-130A is a polycyclic polyether compound belonging to the nigericin group of antibiotics generated by Streptomyces hygroscopicus strain.Formula:C47H78O13Purity:98%Color and Shape:SolidMolecular weight:851.11[Ala92]-p16 (84-103)
CAS:Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.Formula:C93H155N31O26Purity:98%Color and Shape:SolidMolecular weight:2123.44CDK12-IN-4
CAS:CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.432Cdk2/Cyclin Inhibitory Peptide II
CAS:Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Formula:C110H200N48O25Color and Shape:SolidMolecular weight:2595.07CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Formula:C43H49N11O7Color and Shape:SolidMolecular weight:831.92Men 10376
CAS:Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.Formula:C57H68N12O10Purity:98%Color and Shape:SolidMolecular weight:1081.22SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurity:99.96%Color and Shape:SolidMolecular weight:238.28CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Formula:C22H25ClN8OColor and Shape:SolidMolecular weight:452.95LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Formula:C26H29FN6OSColor and Shape:SolidMolecular weight:492.61CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Formula:C34H45N9O2Color and Shape:SolidMolecular weight:611.795PROTAC CDK9 degrader-2
CAS:PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.Formula:C39H36N6O10Purity:98%Color and Shape:SolidMolecular weight:748.74CDK7-IN-1
CAS:CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Formula:C28H35N7O3Color and Shape:SolidMolecular weight:517.634HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Formula:C28H29Cl2F3N4O4Color and Shape:SolidMolecular weight:613.46EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Color and Shape:LiquidCDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurity:98%Color and Shape:Odour SolidCDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Formula:C20H21F2N9Color and Shape:SolidMolecular weight:425.448TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Formula:C40H43BrFN9O11SColor and Shape:SolidMolecular weight:956.791CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.
Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Formula:C46H30ClIrN6O2Color and Shape:SolidMolecular weight:926.44XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Formula:C53H67N11O7SPurity:97.11%Color and Shape:SolidMolecular weight:1002.23CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purity:98%Color and Shape:SolidMolecular weight:285.32EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99Cdk2/Cyclin Inhibitory Peptide I
CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.Formula:C111H196N48O23Purity:98%Color and Shape:SolidMolecular weight:2571.05CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319CDK7-IN-21
CAS:CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .Formula:C33H36FN9O2Color and Shape:SolidMolecular weight:609.7PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Formula:C39H48Cl2N10O5Color and Shape:SolidMolecular weight:807.768IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formula:C44H52Cl2N10O7Purity:98%Color and Shape:SolidMolecular weight:903.85CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Formula:C24H22FN7O2Color and Shape:SolidMolecular weight:459.48EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Formula:C30H20N6OSPurity:98%Color and Shape:SolidMolecular weight:512.58CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Color and Shape:SolidMolecular weight:503.177CDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.464CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Formula:C24H25FN6O3SColor and Shape:SolidMolecular weight:496.56
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
![[Ala92]-p16 (84-103)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP2133.webp&w=3840&q=75)
